Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Laboratory Testing of HIV PrEP in the US

J Infect Dis; ePub 2017 Nov 14; Huang, et al

Laboratory testing for persons taking antiretroviral medication for HIV preexposure prophylaxis (PrEP) is conducted less frequently than recommended by CDC guidelines; however, testing rates increased in the US during the study period of 2011 to 2015. Researchers assessed rates of recommended testing using a commercial insurance claims database and found:

  • Before taking PrEP, 45% of users were tested for HIV, 31% for creatinine, 55% for syphilis, 43% for chlamydia/gonorrhea, and 38% for hepatitis B.
  • By 6 months after PrEP initiation, 38% were tested for HIV, 37% for creatinine, 49% for syphilis, and 39% for chlamydia/gonorrhea.
  • Testing rates increased over the study period but were less frequent than CDC recommendations.

Citation:

Huang YA, Tao G, Samandari T, Hoover KW. Laboratory testing of a cohort of commercially insured users of preexposure prophylaxis in the United States, 2011-2015. [Published online ahead of print November 14, 2017]. J Infect Dis. doi:10.1093/infdis/jix595.